Is percutaneous computed tomography-guided biopsy sufficient to establish indolent lymphoma transformation?
Richter’s syndrome
accuracy rate
core needle
histological types
lymphoma development
Journal
Archives of medical science : AMS
ISSN: 1734-1922
Titre abrégé: Arch Med Sci
Pays: Poland
ID NLM: 101258257
Informations de publication
Date de publication:
Oct 2019
Oct 2019
Historique:
received:
18
06
2018
accepted:
20
09
2018
entrez:
22
11
2019
pubmed:
22
11
2019
medline:
22
11
2019
Statut:
ppublish
Résumé
The aim of the study was to retrospectively evaluate the technical features, efficacy, accuracy, and relevant complications of computed tomography-guided biopsies in various anatomical localizations when diagnosing indolent lymphoma transformations, relapses, duplicate malignant diseases or benign processes. From December 2007 to December 2017, 81 percutaneous biopsy procedures in 72 patients for tumors, sizes 17-232 mm in diameter (median length: 39 mm), were performed in patients with known indolent lymphomas in their clinical history. The patients were men in 41 cases and women in 31 cases, aged 36 to 86 years. In 79 cases (97.5%; 95% CI: 91.3-99.7) results were true positive or true negative; only 2 interventions (2.5%; 95% CI: 0.3-8.6) were histologically false negative. Transformation was verified in 29 cases (35.8%; 95% CI: 25.4-47.2), relapses in 30 cases (37%; 95% CI: 26.6-48.5), duplicate malignancy in 15 cases (18.5%; 95% CI: 10.8-28.7) and benign processes in 7 cases (8.7%; 95% CI: 3.5-17.0). Eight complications in total were revealed, 7 of which were in consequence of thoracic cavity biopsy. A statistically significant relationship between the complication incidence and anatomical localization in the thoracic cavity was identified ( Percutaneous CT guided biopsy performed in patients with a history of indolent lymphoma had high accuracy in establishing the correct diagnosis regarding transformation, relapse, duplicate malignancy or a benign process. Simultaneously, the complication rate was low.
Identifiants
pubmed: 31749872
doi: 10.5114/aoms.2018.79573
pii: 34134
pmc: PMC6855164
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1443-1453Informations de copyright
Copyright: © 2018 Termedia & Banach.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Am J Clin Pathol. 2011 Apr;135(4):516-24
pubmed: 21411774
J Clin Oncol. 2016 Aug 1;34(22):2575-82
pubmed: 27298402
Mayo Clin Proc. 2005 May;80(5):625-31
pubmed: 15887430
J Comput Assist Tomogr. 2005 May-Jun;29(3):369-72
pubmed: 15891509
Blood. 2014 May 1;123(18):2783-90
pubmed: 24615780
Am J Case Rep. 2017 Aug 10;18:878-882
pubmed: 28794405
Ann Hematol. 2017 Apr;96(4):627-637
pubmed: 28130574
Am J Hematol. 2016 Oct;91(10):1032-5
pubmed: 27415417
Best Pract Res Clin Haematol. 2017 Mar - Jun;30(1-2):131-138
pubmed: 28288708
Surg Endosc. 2015 Sep;29(9):2496-9
pubmed: 25492451
Ann Hematol. 2018 Apr;97(4):669-678
pubmed: 29318369
Eur J Surg Oncol. 2015 Jul;41(7):852-8
pubmed: 25980745
Arch Med Sci. 2017 Apr 1;13(3):698-701
pubmed: 28507591
Arch Med Sci. 2016 Apr 1;12(2):448-56
pubmed: 27186193
Br J Cancer. 2015 Apr 28;112(9):1575-84
pubmed: 25867256
J Clin Oncol. 2008 Nov 10;26(32):5165-9
pubmed: 18838711
Ann Oncol. 2018 Mar 1;29(3):544-562
pubmed: 29194473
BMC Cancer. 2018 Mar 12;18(1):281
pubmed: 29530011
World J Surg Oncol. 2015 Mar 27;13:126
pubmed: 25885784
J Clin Ultrasound. 2007 Jul-Aug;35(6):295-301
pubmed: 17486566
Ann Oncol. 2016 Dec;27(12):2149-2160
pubmed: 27701070
Hematol Oncol. 2017 Dec;35(4):440-446
pubmed: 27238634
Int J Hematol. 2015 Feb;101(2):198-202
pubmed: 25416234
Eur J Haematol. 2016 Oct;97(4):379-86
pubmed: 26833691